Evaluation of vaginal brachytherapy for treating early-stage endometrial cancer according to the European Society of Medical Oncology 2020 risk stratification Avrupa Tıbbi Onkoloji Derneği 2020 kılavuzu risk sınıflamasına göre erken evre endometrium kanseri tedavisinde vajinal brakiterapinin etkinliğinin incelenmesi
Turkish Journal of Obstetrics and Gynecology, cilt.19, sa.4, ss.308-314, 2022 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19 Sayı: 4
- Basım Tarihi: 2022
- Doi Numarası: 10.4274/tjod.galenos.2022.47835
- Dergi Adı: Turkish Journal of Obstetrics and Gynecology
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.308-314
- Anahtar Kelimeler: Brachytherapy, adjuvant radiotherapy, vaginal administration, endometrial cancer
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The aim was to evaluate vaginal brachytherapy (VB) after surgery in early-stage endometrial cancer. Materials and Methods: The patients with Stage I-II endometrial adeno-cancer operated between 1998 and 2018 and whose adjuvant therapies had been arranged were evaluated retrospectively. Results: A total of 618 patients were enrolled. In 409 patients in the low-risk group, the vaginal, pelvic recurrence, and distant metastasis rates were found to be higher in the VB group. When the results of 112 patients in the intermediate-risk group were evaluated, there was no statistically significant difference between the vaginal, pelvic recurrence, and distance metastasis rates. In 89 patients in the intermediate-high risk group, vaginal recurrence rates were 0%, 4.8%, 0%, and 25% for VB, external beam radiotherapy, combination radiotherapy, and the follow-up groups, respectively (p=0.010), and pelvic recurrence rates were found to be 18.2%, 0%, 1.9% and 0% (p=0.036). Distant metastasis rates were 0%, 0%, 9.6% and 0% (p=0.229). When the overall survival in all groups was examined, no significant difference was found between the groups. Conclusion: In conclusion, no adjuvant treatment is a proper approach for low-risk patients. Brachytherapy can be considered a suitable option for the intermediate risk group. Combined treatments instead of VB in the high-intermediate risk group would be preferred in terms of local control.